Jason Sheltzer

Last updated

Jason Sheltzer is a cancer biologist at the Yale University School of Medicine. [1]

Contents

Education

Sheltzer received a BA in molecular biology from Princeton University and a PhD in biology from the Massachusetts Institute of Technology. [2] [3] At MIT, Sheltzer performed his PhD research with Angelika Amon on the consequences of aneuploidy. [4] Sheltzer then established his own research group as an independent fellow at Cold Spring Harbor Laboratory. [5] [3] In 2021 Sheltzer was recruited to move his lab to Yale University. [1]

Career and research

Sheltzer uses CRISPR/Cas9 technology to study aneuploidy and cancer genomics. [6] [7] Through the use of chromosome engineering, he has constructed cancer cells with different degrees of aneuploidy, and he has found how aneuploidy affects tumor development and metastasis. [8] [9] [10] In 2019, he discovered a set of copy number alteration biomarkers that can be used to predict cancer patient outcomes. [5] [11] [12] His research has questioned whether anti-cancer drugs could be acting through alternate mechanisms. [13] [14] [15] He is a co-founder of Meliora Therapeutics. [16]

Sheltzer also studies gender disparities in biology research. He discovered that some faculty members, like Nobel Prize winners, tended to hire very few female students in their labs, which could contribute to the gender gap in STEM. [17] [18] [19]

Awards and honors

Related Research Articles

The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 52,000 members in 130 countries and territories. The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

<span class="mw-page-title-main">Jennifer Doudna</span> American biochemist and Nobel laureate (born 1964)

Jennifer Anne Doudna is an American biochemist who has done pioneering work in CRISPR gene editing, and made other fundamental contributions in biochemistry and genetics. Doudna was one of the first women to share a Nobel in the sciences. She received the 2020 Nobel Prize in Chemistry, with Emmanuelle Charpentier, "for the development of a method for genome editing." She is the Li Ka Shing Chancellor's Chair Professor in the department of chemistry and the department of molecular and cell biology at the University of California, Berkeley. She has been an investigator with the Howard Hughes Medical Institute since 1997.

Zena Werb was a professor and the Vice Chair of Anatomy at the University of California, San Francisco. She was also the co-leader of the Cancer, Immunity, and Microenvironment Program at the Hellen Diller Family Comprehensive Cancer Center and a member of the Executive Committee of the Sabre-Sandler Asthma Basic Research Center at UCSF. Her research focused on features of the microenvironment surrounding cells, with particular interest in the extracellular matrix and the role of its protease enzymes in cell signaling.

<span class="mw-page-title-main">Rong Li</span> American cell biologist (born 1967)

Rong Li is the Director of Mechanobiology Institute, a Singapore Research Center of Excellence, at the National University of Singapore. She is a Distinguished Professor at the National University of Singapore's Department of Biological Sciences and Bloomberg Distinguished Professor of Cell Biology and Chemical & Biomolecular Engineering at the Johns Hopkins School of Medicine and Whiting School of Engineering. She previously served as Director of Center for Cell Dynamics in the Johns Hopkins School of Medicine’s Institute for Basic Biomedical Sciences. She is a leader in understanding cellular asymmetry, division and evolution, and specifically, in how eukaryotic cells establish their distinct morphology and organization in order to carry out their specialized functions.

Craig M. Crews is an American scientist at Yale University known for his contributions to chemical biology. He is known for his contributions to the field of induced proximity through his work in creating heterobifunctional molecules that "hijack" cellular processes by inducing the interaction of two proteins inside a living cell. His initial work focused on the discovery of PROteolysis-TArgeting Chimeras (PROTACs) to trigger degradation of disease-causing proteins, a process known as targeted protein degradation (TPD), and he has since developed new versions of -TACs to leverage other cellular processes and protein families to treat disease.

<span class="mw-page-title-main">Nevan Krogan</span> Canadian molecular and systems biologist

Nevan J. Krogan is a Canadian molecular and systems biologist. He is a professor and the Director of the Quantitative Biosciences Institute (QBI) at the University of California San Francisco (UCSF), as well as a senior investigator at the J. David Gladstone Institutes.

Gregory James Hannon is a professor of molecular cancer biology and director of the Cancer Research UK Cambridge Institute at the University of Cambridge. He is a Fellow of Trinity College, Cambridge while also serving as a director of cancer genomics at the New York Genome Center and an adjunct professor at Cold Spring Harbor Laboratory.

JoAnn Trejo is an American pharmacologist, cell biologist, a professor, and also an assistant vice chancellor in the department of health sciences faculty affairs in the Department of Pharmacology at the School of Medicine at University of California, San Diego. She is also the assistant vice chancellor for Health Sciences Faculty Affairs. Trejo studies cell signalling by protease-activated G protein-coupled receptors (GPCRs). She is also actively involved in mentoring, education and outreach activities to increase the diversity of science.

Paul S. Mischel is an American physician-scientist whose laboratory has made pioneering discoveries in the pathogenesis of human cancer. He is currently a Professor and Vice Chair of Research for the Department of Pathology and Institute Scholar of ChEM-H, Stanford University. Mischel was elected into the American Society for Clinical Investigation (ASCI), serving as ASCI president in 2010/11. He was inducted into the Association of American Physicians, and was elected as a fellow of the American Association for the Advancement of Science.

Xiaole Shirley Liu (刘小乐) is computational biologist, cancer researcher, and entrepreneur. She has been a Professor in the Department of Data Sciences at the Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health. She is now the co-founder and CEO of GV20 Therapeutics.

Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.

Professor Jason Carroll is a British medical researcher serving as a Senior Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge and Founder and Chief Scientific Officer of Azeria Therapeutics. He is a Professor of Molecular Oncology assigned to the Department of Oncology and a Fellow of Clare College, Cambridge.

Valentina Greco is an Italian-born biologist who teaches at the Yale School of Medicine as the Carolyn Walch Slayman Professor of Genetics and is an Associate Professor in the Cell Biology and Dermatology departments. Her research focuses on the role of skin stem cells in tissue regeneration.

Christopher Vakoc is a molecular biologist and a professor at Cold Spring Harbor Laboratory.

<span class="mw-page-title-main">Debra Auguste</span> American chemical engineer

Debra Auguste is an American chemical engineer and professor at Northeastern University in the department of chemical engineering. Auguste is dedicated to developing treatments for triple negative breast cancer, one of the most aggressive and fatal cancers that disproportionately affects African American women. Her lab characterizes biomarkers of triple negative breast cancer and develops novel biocompatible therapeutic technologies to target and destroy metastatic cancer cells. Auguste received the 2012 Presidential Early Career Award for Scientists and Engineers and in 2010 was named in the 50 Most Influential African-Americans in Technology. In 2020, Auguste became an Elected Fellow of the American Institute for Medical and Biological Engineering.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

Cigall Kadoch is an American biochemist and cancer biologist who is Associate Professor of Pediatric Oncology at the Dana–Farber Cancer Institute and Harvard Medical School and an Investigator at the Howard Hughes Medical Institute. Her research is focused in chromatin regulation and how changes in cellular structure can lead to human diseases, such as Cancer, Neurodevelopmental disorders, and others. She is internationally recognized for her work on the mammalian SWI/SNF complex, a large molecular machine known as a Chromatin remodeling complex. She was named as one of the world's leading scientists by MIT Technology Review, 35 Under 35 and Forbes 30 Under 30, and a Finalist for the Blavatnik Awards for Young Scientists. In 2019, she received the Martin and Rose Wachtel Cancer Research Prize from the American Association for the Advancement of Science and in 2020, the American Association for Cancer Research Outstanding Achievement in Basic Cancer Research Award. Kadoch was also recognized as one of the 100 Influential Women in Oncology by OncoDaily.

Franziska Michor is an Austrian computational biologist. She is a professor in the department of data science at the Dana–Farber Cancer Institute. She serves as Director of the Physical Sciences-Oncology Center and the Center for Cancer Evolution.

Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. He has been a top executive at several pharmaceutical companies, with respect to the development and clinical testing of novel anticancer drugs and cell therapies. For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA. His honors include being elected a member of the American Society for Clinical Investigation, and the Association of American Physicians.

Marsha A. Moses is an American physician who is the Julia Dyckman Andrus Professor at Harvard Medical School and the Director of the Vascular Biology Program at Boston Children's Hospital. Her research considers the biochemical mechanisms that are responsible for tumor growth and progression. She is a Fellow of the American Institute for Medical and Biological Engineering, the American Academy of Arts and Sciences and the American Association for the Advancement of Science.

References

  1. 1 2 Smith, Cecelia. "Geneticist and Diversity Champion Jason Sheltzer Brings Award-Winning Research Lab to Yale Surgery". medicine.yale.edu. Retrieved 2021-12-26.
  2. ↑ Austin, Jim (2014-07-08). "A Young Tag Team Detects a Major Pipeline Leak". Science | AAAS. Retrieved 2020-06-06.
  3. 1 2 "AACR-Bayer Innovation and Discovery Grants | American Association for Cancer Research". American Association for Cancer Research (AACR). Retrieved 2020-06-06.
  4. ↑ "McKinley and Sheltzer to Receive 2016 Bernfield and Gilula Awards". ASCB. 2016-10-06. Retrieved 2020-06-06.
  5. 1 2 Ricks, Delthia (2018-12-25). "Researcher aims to take uncertainty out of cancer diagnosis". Newsday. Retrieved 2020-06-06.
  6. ↑ "Fox 5 (New York): Modifying Cancer Cell Genomes [The Big Idea]". YouTube . 2018-09-20.
  7. ↑ Kaiser, Jocelyn (2019-09-11). "Some cancer drugs miss their target. CRISPR could improve their aim". Science | AAAS. Retrieved 2020-06-20.
  8. ↑ Seton-Rogers, Sarah (March 2017). "Fitness penalties of aneuploidy". Nature Reviews Cancer. 17 (3): 142–143. doi:10.1038/nrc.2017.9. ISSN   1474-1768. PMID   28184042. S2CID   41054562.
  9. ↑ Seton-Rogers, Sarah (2020-03-31). "Weighing up effects of extra chromosomes". Nature Reviews Cancer. 20 (5): 259. doi: 10.1038/s41568-020-0257-y . ISSN   1474-175X. PMID   32235903. S2CID   214718880.
  10. ↑ Johnson, Carolyn Y. (2023-07-06). "Gene editing helped crack a 100-year-old mystery about cancer". Washington Post. ISSN   0190-8286 . Retrieved 2023-07-16.
  11. ↑ Thomas, Uduak Grace (2018-12-18). "Cancer Genetic Studies Explore Prognostic Value of Copy Number Alterations, Other Biomarkers". GenomeWeb. Retrieved 2020-06-06.
  12. ↑ Dunaief, Daniel. "CSHL's Jason Sheltzer and Google's Joan Smith team up in cancer study | TBR News Media" . Retrieved 2020-06-20.
  13. ↑ Zimmer, Carl (2019-09-11). "Why Aren't Cancer Drugs Better? The Targets Might Be Wrong". The New York Times. ISSN   0362-4331 . Retrieved 2020-06-06.
  14. ↑ Belluz, Julia (2019-09-16). "Most cancer drugs fail in testing. This might be a big reason why". Vox. Retrieved 2020-06-06.
  15. ↑ Preidt, Robert (2019-09-11). "Cancer Drugs Sometimes Work in Unexpected Ways: Study". U.S. News & World Report.
  16. ↑ Gormley, Brian. "Biotech Meliora Therapeutics Gets $11 Million Seed Financing for Cancer Treatments". WSJ. Retrieved 2023-07-16.
  17. ↑ McGregor, Jenna (2014-07-17). "Study: Top labs run by men tend to hire fewer women". The Washington Post.
  18. ↑ Dockterman, Eliana (2014-07-09). "Study: Male Scientists Employ Fewer Women in Labs". Time. Retrieved 2020-06-06.
  19. ↑ Hu, Jane C. (2014-06-30). "Male Professors Rarely Train Female Scientists". Slate Magazine. Retrieved 2020-06-06.
  20. ↑ "Jason Sheltzer, 28". Forbes. Retrieved 2020-06-06.
  21. ↑ "McKinley and Sheltzer to Receive 2016 Bernfield and Gilula Awards". ASCB. 2016-11-07. Retrieved 2020-09-17.
  22. ↑ "President Donald J. Trump Announces Recipients of the Presidential Early Career Award for Scientists and Engineers". whitehouse.gov . Retrieved 2020-06-06– via National Archives.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.